<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, pathophysiology, and causes of gynecomastia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, pathophysiology, and causes of gynecomastia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, pathophysiology, and causes of gynecomastia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn D Braunstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley D Anawalt, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gynecomastia, a benign proliferation of the glandular tissue of the male breast, is common in infancy, adolescence, and in middle-aged to older males. Pseudogynecomastia, which is often seen in males with obesity, refers to fat deposition without glandular proliferation. Gynecomastia must be differentiated from breast carcinoma, which is far less common.</p><p>The epidemiology and pathogenesis will be reviewed here. The causes, evaluation, and management are discussed separately. (See  <a class="medical medical_review" href="/d/html/7476.html" rel="external">"Clinical features, diagnosis, and evaluation of gynecomastia in adults"</a> and  <a class="medical medical_review" href="/d/html/7467.html" rel="external">"Management of gynecomastia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Gynecomastia is defined histologically as a benign proliferation of the glandular tissue of the male breast and clinically by the presence of a rubbery or firm mass extending concentrically from the nipple(s)  (<a class="graphic graphic_figure graphicRef72334" href="/d/graphic/72334.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. Fat deposition without glandular proliferation is termed pseudogynecomastia (lipomastia) and is often seen in obese males.</p><p>The most important differentiation is between gynecomastia and breast carcinoma. Carcinoma is much less common, generally unilateral, eccentric in location rather than symmetrical to the nipple, nontender, hard or firm, often fixed to the underlying tissue, and may be associated with skin dimpling, nipple retraction or discharge, and axillary lymphadenopathy [<a href="#rid2">2,3</a>]. Less common conditions leading to breast enlargement include neurofibromas, lymphangiomas, hematomas, lipomas, and dermoid cysts. (See  <a class="medical medical_review" href="/d/html/7476.html" rel="external">"Clinical features, diagnosis, and evaluation of gynecomastia in adults", section on 'Breast cancer'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Gynecomastia is common in infancy, puberty, and in middle-aged to older males. One estimate is that between 60 to 90 percent of infants have transient gynecomastia due to the high estrogenic milieu of pregnancy [<a href="#rid4">4</a>]. Male infants also have a "mini-puberty" with adult serum concentrations of gonadotropins and a transient rise of serum estradiol more than serum testosterone concentrations [<a href="#rid3">3</a>]. After delivery, gynecomastia regresses in two to three weeks. (See  <a class="medical medical_review" href="/d/html/14310.html" rel="external">"Gynecomastia in children and adolescents"</a>.)</p><p>The second peak is during puberty, with a prevalence ranging from 4 to 69 percent, with a median from several studies of 33 percent  (<a class="graphic graphic_figure graphicRef64368" href="/d/graphic/64368.html" rel="external">figure 2</a>) [<a href="#rid4">4-12</a>]. This wide variation is probably due to differences in what is considered normal subareolar glandular tissue, observer differences, and, probably most importantly, differences in the age distribution of the adolescents examined. Pubertal gynecomastia usually has an onset between ages 10 and 12 years and peaks between ages 13 and 14 years, usually at Tanner pubertal stage 3  (<a class="graphic graphic_table graphicRef76165" href="/d/graphic/76165.html" rel="external">table 1</a>). It generally regresses within 18 months but may persist into adulthood in approximately 20 percent of affected individuals [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/14310.html" rel="external">"Gynecomastia in children and adolescents"</a>.)</p><p>The third peak of gynecomastia occurs in middle-aged and older males. The highest prevalence is at 50 to 80 years, with as many as 24 to 65 percent of males being affected  (<a class="graphic graphic_figure graphicRef64368" href="/d/graphic/64368.html" rel="external">figure 2</a>) [<a href="#rid13">13-18</a>]. </p><p>Although gynecomastia is usually bilateral, it is often asymmetrical and can even be unilateral [<a href="#rid19">19,20</a>]. In a study of 36 male patients who underwent subcutaneous mastectomy for a unilateral breast mass, 30 (83 percent) had gynecomastia, four (11 percent) had lipoma, and two had breast cancer [<a href="#rid20">20</a>]. The majority of patients with gynecomastia were receiving medications that have been associated with gynecomastia  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H4"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H1366796110"><span class="h2">Sex hormone action in breast</span><span class="headingEndMark"> — </span>Estrogens and androgens are the major hormones that determine breast growth and development in females and males. An increased breast tissue ratio of estrogen to androgen effect is necessary to induce breast growth.</p><p>There are three lines of evidence indicating that androgens antagonize the effects of estrogen in breast glandular tissue. First, in vitro data with breast cancer cell lines have predominately shown that androgens have apoptotic and antiproliferative effects [<a href="#rid21">21,22</a>]. Second, in postmenopausal females receiving estrogen and progesterone plus a placebo patch for six months, breast fine needle aspiration biopsies showed a five-fold increase in breast cell proliferation [<a href="#rid23">23</a>]. However, in a group receiving a testosterone patch with the estrogen and progesterone, no increase in cell proliferation was observed. Lastly, in a study of 40 patients with idiopathic gynecomastia, approximately three-quarters had at least a partial resolution of the breast enlargement when treated with dihydrotestosterone, a nonaromatizable androgen [<a href="#rid24">24</a>].</p><p>The various conditions associated with gynecomastia are usually thought to represent an imbalance between the stimulatory effect of estrogen and the inhibitory effect of androgen [<a href="#rid25">25,26</a>]. An imbalance between estrogen and androgen action will occur if there is an increase in free estrogens or a decrease of free androgens that result in an increase in the free estrogen-to-free androgen ratio; androgen insensitivity; or an estrogenic or an antiandrogenic effect of drugs  (<a class="graphic graphic_figure graphicRef58706" href="/d/graphic/58706.html" rel="external">figure 3</a>). </p><p class="headingAnchor" id="H3660554982"><span class="h2">Determinants of sex hormone exposure</span><span class="headingEndMark"> — </span>The factors that define the net estrogen/androgen balance are  (<a class="graphic graphic_table graphicRef53468" href="/d/graphic/53468.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Physiologic stage - physiologic gynecomastia is common and has a trimodal distribution occurring in neonatal, pubertal, and older males </p><p class="bulletIndent1"><span class="glyph">●</span>The circulating concentration and sex-steroid-hormone binding of sex hormone-binding globulin (SHBG)</p><p class="bulletIndent1"><span class="glyph">●</span>The extraglandular conversion of androgens to estrogens, such as in adipose tissue</p><p class="bulletIndent1"><span class="glyph">●</span>The hormone target cells' ability to respond to androgens and estrogens</p><p></p><p class="headingAnchor" id="H3534055225"><span class="h3">Physiologic stage</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal gynecomastia </strong>–<strong> </strong>During pregnancy, the placenta transforms dehydroepiandrosterone and dehydroepiandrosterone sulfate (derived from both the mother and fetus) to <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> (E1) and estradiol (E2), which enter the fetal circulation and stimulate breast glandular proliferation, resulting in transient neonatal gynecomastia. (See  <a class="medical medical_review" href="/d/html/2284.html" rel="external">"Placental development and physiology", section on 'Steroid hormones'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pubertal gynecomastia </strong>–<strong> </strong>In boys who develop gynecomastia during early puberty, a relative increase in extratesticular production of estrogen plays a role in the development of gynecomastia. The major androgen secreted by the adrenal glands is androstenedione. Most of the circulating E1 and E2 in early male puberty are derived from the extraglandular conversion of androstenedione and testosterone via aromatization to E1 and E2, respectively, by tissues that have aromatase including liver, skin, fat, muscle, bone, and kidney. In mid- to late pubertal adolescent boys a greater relative increase in testicular production of estrogen compared with testosterone is the major cause of gynecomastia; after early puberty in males, 95 percent of the circulating testosterone, 15 percent of the E2, and less than 5 percent of E1 is directly secreted by the testes  (<a class="graphic graphic_figure graphicRef58706" href="/d/graphic/58706.html" rel="external">figure 3</a>) [<a href="#rid5">5,27-29</a>]. (See  <a class="medical medical_review" href="/d/html/7474.html" rel="external">"Male reproductive physiology", section on 'Testosterone synthesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Middle-aged and older males </strong>–<strong> </strong>As noted, gynecomastia is most common in middle-aged and older males. The highest prevalence is at 50 to 80 years. This is likely due to a number of factors including the effects of aging and increasing BMI on SHBG  (<a class="graphic graphic_figure graphicRef64368" href="/d/graphic/64368.html" rel="external">figure 2</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="headingAnchor" id="H2949639711"><span class="h3">Role of SHBG</span><span class="headingEndMark"> — </span>The majority of androgens and estrogens that enter the circulation are relatively tightly bound to sex hormone-binding globulin (SHBG) and are weakly bound to albumin. Conditions that increase SHBG concentrations (estrogenic drugs, many antiseizure medications, aging) will decrease free testosterone in males with impaired testosterone production. In addition, SHBG has a higher affinity for androgens than for estrogens, and therefore, any substance that displaces sex hormones from SHBG will tend to displace quantitatively more estrogens than androgens. The unbound or weakly bound androgens and estrogens enter the target cells and lead to hormone action [<a href="#rid30">30,31</a>]. (See  <a class="medical medical_review" href="/d/html/7474.html" rel="external">"Male reproductive physiology", section on 'Transport of gonadal steroids'</a>.)</p><p class="headingAnchor" id="H4110979232"><span class="h3">Obesity</span><span class="headingEndMark"> — </span>In some studies, higher body mass index (BMI) was associated with gynecomastia and breast diameter in adolescents and adults [<a href="#rid16">16,32</a>]. Breast adipose tissue contains the aromatase enzyme complex that converts testosterone and androstenedione to E2 and E1, respectively. Thus, it has been hypothesized, but not proven, that an increase in breast adipose tissue due to generalized weight gain might increase local estrogen production, which in turn may stimulate breast glandular tissue proliferation in a paracrine fashion. </p><p>In addition, the increase in breast fat with weight gain may lead to pseudogynecomastia that might be mistaken for gynecomastia. (See  <a class="medical medical_review" href="/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males", section on 'Obesity'</a>.)</p><p class="headingAnchor" id="H2717841371"><span class="h3">Tissue – specific regulation</span><span class="headingEndMark"> — </span>Some patients with gynecomastia appear to have enhanced sensitivity of the breast tissue to normal circulating estrogen levels even in the presence of normal circulating androgen concentrations. This might reflect increased local aromatization of androgens to estrogens in the breast tissue as increased aromatase activity has been found in pubic skin fibroblasts of patients with pubertal gynecomastia [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H6318343"><span class="h1">CAUSES OF GYNECOMASTIA</span></p><p class="headingAnchor" id="H3317829890"><span class="h2">Common etiologies</span><span class="headingEndMark"> — </span>In<strong> </strong>adult patients with persistent gynecomastia<strong> </strong>seeking<strong> </strong>consultation for the condition, current estimates suggest the following etiologies, all of which are discussed in detail below  (<a class="graphic graphic_table graphicRef53468" href="/d/graphic/53468.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent pubertal gynecomastia – 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Drugs – 10 to 25 percent  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>No detectable abnormality – 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis or malnutrition – 8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hypogonadism – Primary (8 percent), secondary (2 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Testicular tumors – 3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism – 1.5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic kidney disease – 1 percent</p><p></p><p>A series of 786 males with gynecomastia seen at a single institution has confirmed these prevalent etiologies [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H1068114220"><span class="h2">Physiologic</span><span class="headingEndMark"> — </span>As noted above, physiologic gynecomastia is common and has a trimodal distribution occurring in neonatal, pubertal, and older males [<a href="#rid1">1,16</a>]. (See <a class="local">'Epidemiology'</a> above.)</p><p class="headingAnchor" id="H2783437299"><span class="h3">Pubertal gynecomastia</span><span class="headingEndMark"> — </span>It is likely that a transient imbalance of estrogen to androgen accounts for much of the estrogen/androgen imbalance that leads to pubertal gynecomastia. Most studies in pubertal boys with gynecomastia have found no differences in single-point measurements of serum concentrations of testosterone, estradiol (E2), <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> (E1), or gonadotropins from those in normal boys [<a href="#rid7">7,9,35,36</a>]. However, during early puberty, the serum E2 concentrations rise to adult levels before the testosterone concentration, and some reports have shown a transient increase in E2 concentration at the onset of puberty in boys who develop gynecomastia [<a href="#rid7">7</a>]. These boys may also have wider fluctuations of E2 levels, with an absolute increase in 24-hour concentration of E2, which may reflect increased conversion of adrenal androgens to estrogens [<a href="#rid10">10,37</a>]. (See  <a class="medical medical_review" href="/d/html/14310.html" rel="external">"Gynecomastia in children and adolescents"</a>.)</p><p>Leptin and insulin-like growth factor-1 (IGF-1) are elevated in boys with pubertal gynecomastia compared with those without [<a href="#rid38">38-41</a>]. The finding that pubertal gynecomastia occurs in a temporal association with peak height velocity (the time when IGF-1 levels also peak) suggests that, together with estrogens, IGF-1, and/or leptin might play a role in the genesis of pubertal gynecomastia.</p><p class="headingAnchor" id="H4225769482"><span class="h3">Persistent pubertal gynecomastia</span><span class="headingEndMark"> — </span>Pubertal gynecomastia usually resolves spontaneously within six months to two years of onset but, in some instances, it may persist after completion of puberty into adulthood, resulting in persistent pubertal gynecomastia. (See  <a class="medical medical_review" href="/d/html/14310.html" rel="external">"Gynecomastia in children and adolescents"</a>.)</p><p class="headingAnchor" id="H6318937"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>There are many drugs that have been associated with gynecomastia  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>).<strong> </strong>Drugs with the best evidence for an association with gynecomastia are drugs that are known to affect androgen or estrogen concentrations or effects including <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>, <a class="drug drug_general" data-topicid="9265" href="/d/drug information/9265.html" rel="external">cimetidine</a>, <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="9456" href="/d/drug information/9456.html" rel="external">recombinant human growth hormone</a>, estrogens, human chorionic gonadotropin (hCG), antiandrogens, gonadotropin-releasing hormone (GnRH) agonists, and 5-alpha-reductase inhibitors [<a href="#rid42">42,43</a>]. The pathophysiologic mechanism for some, such as estrogens or antiandrogens, is quite clear. However, for others such as spironolactone, the mechanisms are multifactorial.</p><p>For many of the drugs listed in the table, a clear-cut relationship between the drug ingestion and gynecomastia has not been established  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>). For most drugs, the presumed relationship has been based upon epidemiologic studies or challenge-rechallenge studies in small numbers of individual patients [<a href="#rid42">42,44,45</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">Spironolactone</a><strong> </strong>–<strong> </strong>Spironolactone can increase the aromatization of testosterone to E2, decrease the testosterone production rate by the testes, and displace testosterone from sex hormone-binding globulin (SHBG), thereby increasing its metabolic clearance rate. Spironolactone also acts as an antiandrogen by binding to androgen receptors and displacing or preventing binding of testosterone and dihydrotestosterone to their receptors  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>) [<a href="#rid30">30,44</a>]. </p><p></p><p class="bulletIndent1">In a placebo-controlled trial of low-dose <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> (25 to 50 mg/day) for heart failure, endocrine side effects (gynecomastia, breast pain, impotence, and decreased libido) were seen in 10 percent compared with 3 percent in the placebo group [<a href="#rid46">46</a>]. Gynecomastia will occur in almost every male who takes a large dose of spironolactone (≥100 mg/day), eg, to treat males with liver failure or hypertension due to aldosterone excess [<a href="#rid47">47</a>]. </p><p></p><p class="bulletIndent1">In contrast, in a study of <a class="drug drug_general" data-topicid="8789" href="/d/drug information/8789.html" rel="external">eplerenone</a> (a selective mineralocorticoid receptor antagonist without antiandrogen effects) in over 6500 patients with heart failure, gynecomastia, impotence, or breast pain occurred with equal frequency in the eplerenone and placebo groups (1.0 versus 1.1 percent) [<a href="#rid48">48</a>]. A large meta-analysis confirmed these findings [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins </strong>–<strong> </strong>A large epidemiological study has suggested that statin use might be associated with increased risk of gynecomastia. This case-control study adjusted for a number of factors that are associated with gynecomastia and demonstrated an increased relative risk (20 to 40 percent) of gynecomastia with current, recent, or past use of a statin [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium channel blockers </strong>– Drugs within the same class do not cause gynecomastia to the same extent. Among the calcium channel blockers, <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a> has the highest frequency of gynecomastia and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> the lowest [<a href="#rid44">44,51</a>]. Thus, in an older man who is at increased risk of gynecomastia simply on the basis of age, diltiazem would be preferable to nifedipine. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>H2-receptor or proton-pump blockers </strong>–<strong> </strong>Another example is the use of H2-receptor or proton-pump blockers; the incidence of gynecomastia is highest with <a class="drug drug_general" data-topicid="9265" href="/d/drug information/9265.html" rel="external">cimetidine</a> and lowest with <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> [<a href="#rid52">52</a>]. Thus, omeprazole would be a better choice in an older individual with other risk factors for developing gynecomastia  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HAART </strong>–<strong> </strong>The breast enlargement that is seen in males with human immunodeficiency virus (HIV) receiving highly active antiretroviral therapy (HAART) is usually due to fat tissue (lipomastia or pseudogynecomastia) as part of a fat redistribution syndrome (lipodystrophy) [<a href="#rid53">53</a>]. However, cases of true gynecomastia have also been described, thought to be due to coexisting hypogonadism or possible estrogen-like effects of some drugs, in particular, <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>) [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/3733.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"</a> and  <a class="medical medical_review" href="/d/html/3700.html" rel="external">"Treatment of HIV-associated lipodystrophy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostate cancer: androgen deprivation therapy </strong>–<strong> </strong>Gynecomastia is common in males with prostate cancer undergoing androgen deprivation therapy, in particular with <a class="drug drug_general" data-topicid="9154" href="/d/drug information/9154.html" rel="external">bicalutamide</a>. The prevalence is as high as 75 percent when antiandrogen monotherapy is used but is only approximately 15 percent in males treated with total androgen blockade (combined GnRH agonist with an antiandrogen). This difference might be due to higher doses of antiandrogen plus persistent normal to elevated endogenous production of estrogen with antiandrogen therapy. When antiandrogens are used as monotherapy, much higher doses are used, eg, bicalutamide 150 mg/day versus 50 mg/day if combined with a GnRH agonist.  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>) (See  <a class="medical medical_review" href="/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Gynecomastia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herbal products </strong>–<strong> </strong>Tea tree oil and lavender oil, plant-derived oils that are available as over-the-counter skin care products (lotions, soaps, and shampoos), have been associated with gynecomastia. A few prepubertal boys have been reported to develop gynecomastia after repeated use of skin products containing the oils [<a href="#rid55">55</a>]. In vitro studies demonstrated weak estrogenic and antiandrogenic properties of both oils, and the gynecomastia resolved when the skin products were discontinued. Other environmental substances with estrogenic or antiandrogenic properties have also been reported to cause gynecomastia [<a href="#rid56">56-58</a>]. </p><p></p><p class="bulletIndent1">However, in a cross-sectional study of 556 children with a mean age of 6.3 years, 74 percent of whom had been exposed to lavender oil, tea tree oil or both, no cases of prepubertal gynecomastia or premature thelarche were diagnosed [<a href="#rid59">59</a>]. In addition, one study of soy protein formula, which contains phytoestrogens, was not associated with gynecomastia in one study of children [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H6318955"><span class="h2">Idiopathic</span><span class="headingEndMark"> — </span>Gynecomastia in adults is usually multifactorial. There tends to be a gradual decrease in testosterone production in older males and an increase in SHBG levels, resulting in a fall in the total and free testosterone concentration with a reciprocal increase in the luteinizing hormone (LH) level that results in increased aromatization of testosterone to estradiol [<a href="#rid28">28,61</a>]. In addition, aging is associated with increased body fat relative to the lean body mass. Adipose tissue is a site of extraglandular aromatization of androstenedione to E1 and testosterone to E2. These two factors probably account for most patients who have "idiopathic" gynecomastia. Older males are also more likely to take medications associated with gynecomastia than are younger males.</p><p class="headingAnchor" id="H6318961"><span class="h2">Cirrhosis</span><span class="headingEndMark"> — </span>The prevalence of gynecomastia in cirrhotic patients is as high as 67 percent; however, this may not be significantly different from noncirrhotic, age-matched control patients [<a href="#rid26">26,62</a>]. Cirrhosis is accompanied by several changes that probably explain the development of gynecomastia, including an increased production rate of androstenedione from the adrenals, enhanced aromatization of androstenedione to E1, and increased conversion of E1 to E2 [<a href="#rid63">63</a>]. Additionally, many patients receive high doses of <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>, which can contribute to the pathogenesis of gynecomastia in this population. (See  <a class="medical medical_review" href="/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Chest findings'</a>.)</p><p class="headingAnchor" id="H814974332"><span class="h2">Starvation and refeeding</span><span class="headingEndMark"> — </span>Several studies were carried out on American prisoners of war who were freed at the end of World War II. Approximately 10 percent had developed gynecomastia during starvation, while between 5 and 50 percent noted breast tenderness, pain, and enlargement within two to three months of refeeding after release [<a href="#rid64">64</a>]. Prior to refeeding, approximately 80 percent reported erectile dysfunction, 85 percent had decreased libido, and 73 percent showed testicular atrophy [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a>.)</p><p>During starvation, both gonadotropin and testosterone levels were probably reduced, while estrogen production was probably normal due to normal estrogen production from adrenal precursors. These changes will promote the development of gynecomastia. During refeeding, gonadotropins rise, resulting in both an increase in testosterone secretion and a marked elevation in E2 product (due to LH-induced increases in aromatization of testosterone) that mimics normal puberty [<a href="#rid65">65</a>]. Thus, patients who develop refeeding gynecomastia may be said to have undergone a "second puberty." (See  <a class="medical medical_review" href="/d/html/5849.html" rel="external">"Normal puberty", section on 'Boys'</a>.)</p><p class="headingAnchor" id="H6318967"><span class="h2">Male hypogonadism</span><span class="headingEndMark"> — </span>Primary hypogonadism can be due to a congenital abnormality, such as Klinefelter syndrome or an enzymatic defect in the testosterone biosynthetic pathway, or to testicular trauma, infection, infiltrative disorders, vascular insufficiency, or aging (see  <a class="medical medical_review" href="/d/html/7459.html" rel="external">"Causes of primary hypogonadism in males"</a>). The associated reduction in testosterone production leads to a decrease in the serum testosterone concentration and a compensatory rise in LH release. The excess LH results in enhanced Leydig cell stimulation with inhibition of the 17,20-lyase and 17-hydroxylase activities and increased aromatization of testosterone to E2; the net effect is an increase in E2 relative to testosterone secretion [<a href="#rid66">66</a>].</p><p>Secondary hypogonadism due to a hypothalamic or pituitary abnormality is less commonly associated with gynecomastia. In these patients, the production of LH is deficient, resulting in a low testosterone production rate and low E2 production from the testes. However, the adrenal cortex continues to produce estrogen precursors that are aromatized in extraglandular tissue; the result is an increased estrogen-to-androgen ratio.</p><p>Men with hyperprolactinemia may develop gynecomastia due to prolactin's effect on reducing the secretion of gonadotropins, leading to secondary hypogonadism. Prolactin itself will stimulate milk production in breast tissue that has been primed by estrogen and progesterone but does not directly cause gynecomastia.</p><p class="headingAnchor" id="H6318973"><span class="h2">Testicular neoplasms</span><span class="headingEndMark"> — </span>Germ cell tumors account for approximately 95 percent of testicular neoplasms; between 7 and 11 percent of affected patients have gynecomastia determined by physical examination and 23.4 percent by computed tomography (CT) imaging criteria at the time of presentation [<a href="#rid67">67</a>]. The gynecomastia is associated with secretion of hCG by foci of choriocarcinoma or trophoblastic cells in germ cell tumors  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors"</a>.) </p><p>The high levels of hCG lead to Leydig cell dysfunction through inhibition of the cytochrome P450c17 enzyme, which mediates the 17,20-lyase and 17-hydroxylase activities in the testes [<a href="#rid66">66</a>]. hCG also stimulates interstitial (Leydig) cell aromatase activity, which converts androgen precursors to E1 and E2. The net effect is a relative increase in E2 to testosterone production.</p><p>Gynecomastia is a poor prognostic sign if present at the time of diagnosis of the tumor [<a href="#rid67">67</a>], although this has been disputed [<a href="#rid68">68</a>]. It also occurs in approximately 15 percent of patients after successful treatment with surgery, chemotherapy, or radiation therapy; post-therapy gynecomastia does not affect predicted survival [<a href="#rid69">69</a>]. This form of gynecomastia results from hypogonadism secondary to the chemotherapy or radiation; hCG is not found in the serum. It often spontaneously resolves within one year [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer"</a>.)</p><p>Gynecomastia is also found in 20 to 30 percent of patients with the less common (2 percent of all testicular tumors) Leydig cell tumors of the testes [<a href="#rid70">70,71</a>]. These tumors are found in 6- to 10-year-old boys who present with precocious puberty and in 26- to 35-year-old males who present with a testicular mass, gynecomastia, erectile dysfunction, and loss of libido. Approximately 10 percent of these tumors are malignant. In boys, Leydig cell tumors may secrete testosterone and/or E2, but they usually secrete relatively increased quantities of E2. They also aromatize androgen precursors to estrogens [<a href="#rid72">72,73</a>]. In adults, testosterone production is generally decreased because the increased E2 levels inhibit gonadotropin secretion, which in turn leads to secondary hypogonadism. (See  <a class="medical medical_review" href="/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors"</a>.)</p><p>Large cell calcifying Sertoli cell (sex-cord) tumors of the testes are associated with gynecomastia and feminization through excessive aromatase activity, converting androstenedione to E1 and testosterone to E2. These tumors may occur sporadically or as manifestations of two autosomal dominant disorders: Peutz-Jeghers syndrome and the Carney complex. (See  <a class="medical medical_review" href="/d/html/2972.html" rel="external">"Testicular sex cord stromal tumors", section on 'Sertoli cell tumors'</a>.)</p><p class="headingAnchor" id="H6318979"><span class="h2">Hyperthyroidism</span><span class="headingEndMark"> — </span>Gynecomastia has been reported in as many as 25 to 40 percent of males with hyperthyroidism due to Graves' disease, although one study suggests that the prevalence is less than 10 percent [<a href="#rid74">74-77</a>]. Serum LH levels are often elevated, contributing to increased E2 relative to testosterone production by Leydig cells [<a href="#rid78">78,79</a>]. There is also enhanced aromatization of testosterone to E2 and of androstenedione to E1 in extraglandular tissues [<a href="#rid80">80</a>]. This results in increased concentration of SHBG. Free testosterone levels are normal or low, while free E2 levels are elevated. Thus, gynecomastia results from the combination of decreased free androgen levels combined with the overproduction of estrogens. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Genitourinary'</a>.)</p><p class="headingAnchor" id="H6318985"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>Gynecomastia occurs in approximately 50 percent of patients treated with maintenance hemodialysis [<a href="#rid81">81</a>]. The primary cause of the gynecomastia appears to be Leydig cell dysfunction. Serum testosterone levels are low, and gonadotropins are appropriately elevated; the metabolic clearance of LH is also reduced [<a href="#rid82">82</a>]. Gynecomastia may occur following renal transplantation as gonadal function improves ("refeeding gynecomastia") and/or the use of transplantation medications such as <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>.</p><p class="headingAnchor" id="H6318991"><span class="h2">Other rare causes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Feminizing adrenal tumors</strong> – These are rare tumors that are typically large at the time of presentation and are malignant in approximately 75 percent of cases, with a median survival of 1.5 years. In a series of 52 patients, 98 percent had gynecomastia, 58 percent had a palpable tumor, and approximately 50 percent had testicular atrophy [<a href="#rid83">83</a>]. Serum levels of dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, and E2 are increased, while total and free testosterone levels are reduced. Urinary 17-ketosteroid excretion is generally markedly elevated. Gonadotropin levels are usually normal or low. The combination of increased secretion of estrogens by the tumor and increased peripheral aromatization of adrenal androgens to estrogens accounts for the gynecomastia [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ectopic hCG</strong> – Increased serum levels of immunoreactive hCG are found in approximately 18 percent of patients with a wide variety of nontrophoblastic neoplasms [<a href="#rid85">85</a>]. The levels of hCG are generally only modestly raised, and most patients do not exhibit clinical evidence of excess hCG production, in part because the majority of patients have production of the biologically inactive free beta subunit of hCG rather than the biologically active intact molecule. There are, however, a few exceptions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Precocious puberty can occur in boys with hCG-secreting hepatoblastomas [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In adults, large cell carcinoma of the lung, gastric carcinoma, renal cell carcinoma, and, occasionally, hepatoma have been associated with gynecomastia and marked elevations of serum hCG.</p><p></p><p class="bulletIndent1">The pathogenesis of the gynecomastia is similar to that found with hCG-secreting germ cell neoplasms of the testes. (See  <a class="medical medical_review" href="/d/html/2980.html" rel="external">"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors", section on 'Serum tumor markers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders of sex development</strong> – Individuals with a disorder of sex development born with both testicular and ovarian tissue may develop gynecomastia from excessive estrogen secretion by the ovarian component [<a href="#rid86">86</a>]. In addition, the increased estrogen production can suppress intratesticular P450c17 activity, as well as LH secretion, thereby reducing testosterone production.</p><p></p><p class="bulletIndent1">The androgen insensitivity syndromes are a group of disorders due to defects in or absence of the intracellular androgen receptor in androgen target tissues [<a href="#rid87">87,88</a>]. The clinical manifestations are variable, but breast development is seen. This disorder is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial prepubertal gynecomastia</strong> – Familial prepubertal gynecomastia is a rare disorder of increased aromatase activity resulting in severe estrogen excess. The disorder appears to be due to heterozygous inversions or polymorphisms of the p450 aromatase gene (<em>CYP19</em>) with autosomal dominant inheritance [<a href="#rid89">89-95</a>]. </p><p></p><p class="bulletIndent1">This rare syndrome is characterized by pre- or peripubertal gynecomastia that is always bilateral [<a href="#rid94">94,95</a>]. Patients typically have small testes, advanced bone age with short stature as adults, and a high-pitched voice.</p><p></p><p class="bulletIndent1">It is possible that some patients with the diagnosis of "idiopathic" gynecomastia actually represent excessive extraglandular aromatase activity [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1">Aromatase inhibitors, which have had limited success in the treatment of other causes of gynecomastia, may be effective in this disorder [<a href="#rid89">89</a>].</p><p></p><p class="headingAnchor" id="H10403929"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16107.html" rel="external">"Patient education: Gynecomastia (male breast development) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2186.html" rel="external">"Patient education: Gynecomastia (breast enlargement in males) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions </strong>–<strong> </strong>Gynecomastia is defined histologically as a benign proliferation of the glandular tissue of the male breast and clinically by the presence of a rubbery or firm mass extending concentrically from the nipple(s)  (<a class="graphic graphic_figure graphicRef72334" href="/d/graphic/72334.html" rel="external">figure 1</a>). Fat deposition without glandular proliferation is termed pseudogynecomastia (lipomastia; often seen in obese males). (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>–<strong> </strong>Gynecomastia is common in infancy and adolescence. It is estimated that between 60 to 90 percent of infants have transient gynecomastia due to the high estrogenic milieu of pregnancy. The second peak of occurrence is during puberty, affecting approximately one- to two-thirds of boys. Spontaneous regression of breast tissue occurs in most cases. (See  <a class="medical medical_review" href="/d/html/14310.html" rel="external">"Gynecomastia in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology </strong>–<strong> </strong>The basic pathophysiology of gynecomastia is an imbalance in androgen-to-estrogen concentrations or effect due to decreased androgen production, increased estrogen production, antiandrogen, or estrogenic drugs or compounds. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes </strong>–<strong> </strong>In adult patients seeking help for gynecomastia, current estimates suggest the following etiologies  (<a class="graphic graphic_table graphicRef53468" href="/d/graphic/53468.html" rel="external">table 3</a>) (see <a class="local">'Epidemiology'</a> above and <a class="local">'Causes of gynecomastia'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No detectable abnormality – 25 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Persistent pubertal gynecomastia – 25 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Drugs – 10 to 25 percent  (<a class="graphic graphic_table graphicRef71421" href="/d/graphic/71421.html" rel="external">table 2</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Cirrhosis or malnutrition – 8 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Male hypogonadism – 10 percent; (primary hypogonadism [8 percent], secondary hypogonadism [2 percent])</p><p class="bulletIndent2"><span class="glyph">•</span>Testicular tumors – 3 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Untreated hyperthyroidism – 1.5 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease – 1 percent</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.</a></li><li><a class="nounderline abstract_t">Giordano SH. Breast Cancer in Men. N Engl J Med 2018; 378:2311.</a></li><li><a class="nounderline abstract_t">Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology 2019; 7:778.</a></li><li><a class="nounderline abstract_t">Schmidt-Voigt J. Brustdruenschwellungen bei mannlichen Jugendlichen des Pubertatsalters (Pubertatsmakromastie). Z Kinderheilkd 1941; 62:590.</a></li><li><a class="nounderline abstract_t">Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490.</a></li><li><a class="nounderline abstract_t">NYDICK M, BUSTOS J, DALE JH Jr, RAWSON RW. Gynecomastia in adolescent boys. JAMA 1961; 178:449.</a></li><li><a class="nounderline abstract_t">Lee PA. The relationship of concentrations of serum hormones to pubertal gynecomastia. J Pediatr 1975; 86:212.</a></li><li><a class="nounderline abstract_t">Fara GM, Del Corvo G, Bernuzzi S, et al. Epidemic of breast enlargement in an Italian school. Lancet 1979; 2:295.</a></li><li><a class="nounderline abstract_t">Harlan WR, Grillo GP, Cornoni-Huntley J, Leaverton PE. Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey. J Pediatr 1979; 95:293.</a></li><li><a class="nounderline abstract_t">Moore DC, Schlaepfer LV, Paunier L, Sizonenko PC. Hormonal changes during puberty: V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab 1984; 58:492.</a></li><li><a class="nounderline abstract_t">Biro FM, Lucky AW, Huster GA, Morrison JA. Hormonal studies and physical maturation in adolescent gynecomastia. J Pediatr 1990; 116:450.</a></li><li><a class="nounderline abstract_t">Kumanov P, Deepinder F, Robeva R, et al. Relationship of adolescent gynecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys. J Adolesc Health 2007; 41:126.</a></li><li><a class="nounderline abstract_t">WILLIAMS MJ. Gynecomastia. Its incidence, recognition and host characterization in 447 autopsy cases. Am J Med 1963; 34:103.</a></li><li><a class="nounderline abstract_t">Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab 1979; 48:338.</a></li><li><a class="nounderline abstract_t">Carlson HE. Gynecomastia. N Engl J Med 1980; 303:795.</a></li><li><a class="nounderline abstract_t">Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. Am J Med 1984; 77:633.</a></li><li><a class="nounderline abstract_t">Murray NP, Daly MJ. Gynaecomastia and heart failure--adverse drug reaction or disease process? J Clin Pharm Ther 1991; 16:275.</a></li><li><a class="nounderline abstract_t">Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol 1994; 21:579.</a></li><li><a class="nounderline abstract_t">O'Hanlon DM, Kent P, Kerin MJ, Given HF. Unilateral breast masses in men over 40: a diagnostic dilemma. Am J Surg 1995; 170:24.</a></li><li><a class="nounderline abstract_t">Volpe CM, Raffetto JD, Collure DW, et al. Unilateral male breast masses: cancer risk and their evaluation and management. Am Surg 1999; 65:250.</a></li><li><a class="nounderline abstract_t">Dimitrakakis C, Zhou J, Bondy CA. Androgens and mammary growth and neoplasia. Fertil Steril 2002; 77 Suppl 4:S26.</a></li><li><a class="nounderline abstract_t">Somboonporn W, Davis SR, National Health and Medical Research Council. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004; 25:374.</a></li><li><a class="nounderline abstract_t">Hofling M, Hirschberg AL, Skoog L, et al. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007; 14:183.</a></li><li><a class="nounderline abstract_t">Kuhn JM, Roca R, Laudat MH, et al. Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone. Clin Endocrinol (Oxf) 1983; 19:513.</a></li><li><a class="nounderline abstract_t">Rochefort H, Garcia M. The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmacol Ther 1983; 23:193.</a></li><li><a class="nounderline abstract_t">Edmondson HA, Glass SJ, Soll SN. Gynecomastia associated with cirrhosis of the liver. Proc Soc Exp Biol Med 1939; 42:97.</a></li><li><a class="nounderline abstract_t">Wilson JD, Aiman J, MacDonald PC. The pathogenesis of gynecomastia. Adv Intern Med 1980; 25:1.</a></li><li><a class="nounderline abstract_t">Smals AG. Gynaecomastia. Neth J Med 1987; 31:47.</a></li><li><a class="nounderline abstract_t">Weinstein RL, Kelch RP, Jenner MR, et al. Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin. J Clin Invest 1974; 53:1.</a></li><li><a class="nounderline abstract_t">Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977; 87:398.</a></li><li><a class="nounderline abstract_t">Grosso DS, Boyden TW, Pamenter RW, et al. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob Agents Chemother 1983; 23:207.</a></li><li><a class="nounderline abstract_t">Ersöz Hö, Onde ME, Terekeci H, et al. Causes of gynaecomastia in young adult males and factors associated with idiopathic gynaecomastia. Int J Androl 2002; 25:312.</a></li><li><a class="nounderline abstract_t">Bulard J, Mowszowicz I, Schaison G. Increased aromatase activity in pubic skin fibroblasts from patients with isolated gynecomastia. J Clin Endocrinol Metab 1987; 64:618.</a></li><li><a class="nounderline abstract_t">Mieritz MG, Christiansen P, Jensen MB, et al. Gynaecomastia in 786 adult men: clinical and biochemical findings. Eur J Endocrinol 2017; 176:555.</a></li><li><a class="nounderline abstract_t">Knorr D, Bidlingmaier F. Gynaecomastia in male adolescents. Clin Endocrinol Metab 1975; 4:157.</a></li><li><a class="nounderline abstract_t">Bidlingmaier F, Knorr D. Plasma testosterone and estrogens in pubertal gynecomastia. Z Kinderheilkd 1973; 115:89.</a></li><li><a class="nounderline abstract_t">Large DM, Anderson DC. Twenty-four hour profiles of circulating androgens and oestrogens in male puberty with and without gynaecomastia. Clin Endocrinol (Oxf) 1979; 11:505.</a></li><li><a class="nounderline abstract_t">Limony Y, Friger M, Hochberg Z. Pubertal gynecomastia coincides with peak height velocity. J Clin Res Pediatr Endocrinol 2013; 5:142.</a></li><li><a class="nounderline abstract_t">Mieritz MG, Sorensen K, Aksglaede L, et al. Elevated serum IGF-I, but unaltered sex steroid levels, in healthy boys with pubertal gynaecomastia. Clin Endocrinol (Oxf) 2014; 80:691.</a></li><li><a class="nounderline abstract_t">Mieritz MG, Rakêt LL, Hagen CP, et al. A Longitudinal Study of Growth, Sex Steroids, and IGF-1 in Boys With Physiological Gynecomastia. J Clin Endocrinol Metab 2015; 100:3752.</a></li><li><a class="nounderline abstract_t">Dundar B, Dundar N, Erci T, et al. Leptin levels in boys with pubertal gynecomastia. J Pediatr Endocrinol Metab 2005; 18:929.</a></li><li><a class="nounderline abstract_t">Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf 2012; 11:779.</a></li><li><a class="nounderline abstract_t">Hagberg KW, Divan HA, Fang SC, et al. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Epidemiol 2017; 9:83.</a></li><li><a class="nounderline abstract_t">Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy 1993; 13:37.</a></li><li><a class="nounderline abstract_t">Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. Eur J Clin Pharmacol 2015; 71:569.</a></li><li><a class="nounderline abstract_t">Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.</a></li><li><a class="nounderline abstract_t">Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999; 131:105.</a></li><li><a class="nounderline abstract_t">Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.</a></li><li><a class="nounderline abstract_t">De Vecchis R, Cantatrione C, Mazzei D, et al. The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials. J Clin Med Res 2017; 9:130.</a></li><li><a class="nounderline abstract_t">Skeldon SC, Carleton B, Brophy JM, et al. Statin medications and the risk of gynecomastia. Clin Endocrinol (Oxf) 2018; 89:470.</a></li><li><a class="nounderline abstract_t">Tanner LA, Bosco LA. Gynecomastia associated with calcium channel blocker therapy. Arch Intern Med 1988; 148:379.</a></li><li><a class="nounderline abstract_t">García Rodríguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994; 308:503.</a></li><li><a class="nounderline abstract_t">Pantanowitz L, Sen S, Crisi GM, et al. Spectrum of breast disease encountered in HIV-positive patients at a community teaching hospital. Breast 2011; 20:303.</a></li><li><a class="nounderline abstract_t">Jover F, Cuadrado JM, Roig P, et al. Efavirenz-associated gynecomastia: report of five cases and review of the literature. Breast J 2004; 10:244.</a></li><li><a class="nounderline abstract_t">Ramsey JT, Li Y, Arao Y, et al. Lavender Products Associated With Premature Thelarche and Prepubertal Gynecomastia: Case Reports and Endocrine-Disrupting Chemical Activities. J Clin Endocrinol Metab 2019; 104:5393.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, McCully WF, MacLaughlin DT, et al. The mortician's mystery. Gynecomastia and reversible hypogonadotropic hypogonadism in an embalmer. N Engl J Med 1988; 318:961.</a></li><li><a class="nounderline abstract_t">Brody SA, Loriaux DL. Epidemic of gynecomastia among haitian refugees: exposure to an environmental antiandrogen. Endocr Pract 2003; 9:370.</a></li><li><a class="nounderline abstract_t">Braunstein GD. Environmental gynecomastia. Endocr Pract 2008; 14:409.</a></li><li><a class="nounderline abstract_t">Hawkins J, Hires C, Dunne E, Keenan L. Prevalence of endocrine disorders among children exposed to Lavender Essential Oil and Tea Tree Essential Oils. Int J Pediatr Adolesc Med 2022; 9:117.</a></li><li><a class="nounderline abstract_t">Giampietro PG, Bruno G, Furcolo G, et al. Soy protein formulas in children: no hormonal effects in long-term feeding. J Pediatr Endocrinol Metab 2004; 17:191.</a></li><li><a class="nounderline abstract_t">Swerdloff RS, Wang C. Androgen deficiency and aging in men. West J Med 1993; 159:579.</a></li><li><a class="nounderline abstract_t">Cavanaugh J, Niewoehner CB, Nuttall FQ. Gynecomastia and cirrhosis of the liver. Arch Intern Med 1990; 150:563.</a></li><li><a class="nounderline abstract_t">Gordon GG, Olivo J, Rafil F, Southren AL. Conversion of androgens to estrogens in cirrhosis of the liver. J Clin Endocrinol Metab 1975; 40:1018.</a></li><li><a class="nounderline abstract_t">JACOBS EC. Gynecomastia following severe starvation. Ann Intern Med 1948; 28:792.</a></li><li><a class="nounderline abstract_t">Smith SR, Chhetri MK, Johanson J, et al. The pituitary-gonadal axis in men with protein-calorie malnutrition. J Clin Endocrinol Metab 1975; 41:60.</a></li><li><a class="nounderline abstract_t">Forest MG, Lecoq A, Saez JM. Kinetics of human chorionic gonadotropin-induced steroidogenic response of the human testis. II. Plasma 17 alpha-hydroxyprogesterone, delta4-androstenedione, estrone, and 17 beta-estradiol: evidence for the action of human chorionic gonadotropin on intermediate enzymes implicated in steroid biosynthesis. J Clin Endocrinol Metab 1979; 49:284.</a></li><li><a class="nounderline abstract_t">Klang E, Rozendorn N, Raskin S, et al. CT measurement of breast glandular tissue and its association with testicular cancer. Eur Radiol 2017; 27:536.</a></li><li><a class="nounderline abstract_t">Polat AV, Öztürk M, Çamlıdağ İ, Akyüz B. Is gynecomastia related to the disease characteristics and prognosis in testicular germ cell tumor patients? Diagn Interv Radiol 2019; 25:189.</a></li><li><a class="nounderline abstract_t">Turner AR, Morrish DW, Berry J, MacDonald RN. Gynecomastia after cytotoxic therapy for metastatic testicular cancer. Arch Intern Med 1982; 142:896.</a></li><li><a class="nounderline abstract_t">Gabrilove JL, Nicolis GL, Mitty HA, Sohval AR. Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature. Cancer 1975; 35:1184.</a></li><li><a class="nounderline abstract_t">Bercovici JP, Tater D, Khoury S, et al. Leydig cell tumor with gynecomastia: hormonal effects of an estrogen-producing tumor. J Clin Endocrinol Metab 1981; 53:1291.</a></li><li><a class="nounderline abstract_t">Suardi N, Strada E, Colombo R, et al. Leydig cell tumour of the testis: presentation, therapy, long-term follow-up and the role of organ-sparing surgery in a single-institution experience. BJU Int 2009; 103:197.</a></li><li><a class="nounderline abstract_t">Braunstein GD. Aromatase and gynecomastia. Endocr Relat Cancer 1999; 6:315.</a></li><li><a class="nounderline abstract_t">Chopra IJ, Tulchinsky D. Status of estrogen-androgen balance in hyperthyroid men with Graves' disease. J Clin Endocrinol Metab 1974; 38:269.</a></li><li><a class="nounderline abstract_t">Ashkar FS, Smoak WM 3rd, Gilson AJ, Miller R. Gynecomastia and mastoplasia in Graves' disease. Metabolism 1970; 19:946.</a></li><li><a class="nounderline abstract_t">Chan WB, Yeung VT, Chow CC, et al. Gynaecomastia as a presenting feature of thyrotoxicosis. Postgrad Med J 1999; 75:229.</a></li><li><a class="nounderline abstract_t">Bercovici JP, Mauvais-Jarvis P. Hyperthyroidism and gynecomastia: metabolic studies. J Clin Endocrinol Metab 1972; 35:671.</a></li><li><a class="nounderline abstract_t">Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974; 3:69.</a></li><li><a class="nounderline abstract_t">Abalovich M, Levalle O, Hermes R, et al. Hypothalamic-pituitary-testicular axis and seminal parameters in hyperthyroid males. Thyroid 1999; 9:857.</a></li><li><a class="nounderline abstract_t">Olivo J, Gordon GG, Rafii F, Southren AL. Estrogen metabolism in hyperthyroidism and in cirrhosis of the liver. Steroids 1975; 26:47.</a></li><li><a class="nounderline abstract_t">Freeman RM, Lawton RL, Fearing MO. Gynecomastia: an endocrinologic complication of hemodialysis. Ann Intern Med 1968; 69:67.</a></li><li><a class="nounderline abstract_t">Holdsworth S, Atkins RC, de Kretser DM. The pituitary-testicular axis in men with chronic renal failure. N Engl J Med 1977; 296:1245.</a></li><li><a class="nounderline abstract_t">GABRILOVE JL, SHARMA DC, WOTIZ HH, DORFMAN RI. FEMINIZING ADRENOCORTICAL TUMORS IN THE MALE. A REVIEW OF 52 CASES INCLUDING A CASE REPORT. Medicine (Baltimore) 1965; 44:37.</a></li><li><a class="nounderline abstract_t">Kidd MT, Karlin NJ, Cook CB. Feminizing adrenal neoplasms: case presentations and review of the literature. J Clin Oncol 2011; 29:e127.</a></li><li class="breakAll">Braunstein GD. Placental proteins as tumor markers. In: Immunodiagnosis of cancer, Herberman RB, Mercer DW (Eds), Marcel Dekker, New York 1990. p.673.</li><li class="breakAll">van Niekerk WA. True hermaphroditism. In: The Intersex Child, Josso N (Ed), S Karger AG, Basel, Switzerland 1981. p.80.</li><li><a class="nounderline abstract_t">Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995; 16:271.</a></li><li><a class="nounderline abstract_t">Hellmann P, Christiansen P, Johannsen TH, et al. Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, reproductive hormones and the development of gynaecomastia. Arch Dis Child 2012; 97:403.</a></li><li><a class="nounderline abstract_t">Binder G, Iliev DI, Dufke A, et al. Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred. J Clin Endocrinol Metab 2005; 90:484.</a></li><li><a class="nounderline abstract_t">Berkovitz GD, Guerami A, Brown TR, et al. Familial gynecomastia with increased extraglandular aromatization of plasma carbon19-steroids. J Clin Invest 1985; 75:1763.</a></li><li><a class="nounderline abstract_t">Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003; 348:1855.</a></li><li><a class="nounderline abstract_t">Fukami M, Tsuchiya T, Vollbach H, et al. Genomic basis of aromatase excess syndrome: recombination- and replication-mediated rearrangements leading to CYP19A1 overexpression. J Clin Endocrinol Metab 2013; 98:E2013.</a></li><li><a class="nounderline abstract_t">Stratakis CA. An aroma of complexity: how the unique genetics of aromatase (CYP19A1) explain diverse phenotypes from hens and hyenas to human gynecomastia, and testicular and other tumors. J Clin Endocrinol Metab 2013; 98:4676.</a></li><li><a class="nounderline abstract_t">Shozu M, Fukami M, Ogata T. Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis. Expert Rev Endocrinol Metab 2014; 9:397.</a></li><li><a class="nounderline abstract_t">Fukami M, Miyado M, Nagasaki K, et al. Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia. Pediatr Endocrinol Rev 2014; 11:298.</a></li></ol></div><div id="topicVersionRevision">Topic 7466 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17881754" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice. Gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29897847" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Breast Cancer in Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31099174" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : EAA clinical practice guidelines-gynecomastia evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Brustdruenschwellungen bei mannlichen Jugendlichen des Pubertatsalters (Pubertatsmakromastie)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8421478" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14480779" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Gynecomastia in adolescent boys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1111683" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The relationship of concentrations of serum hormones to pubertal gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/88620" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemic of breast enlargement in an Italian school.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/448573" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6693546" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hormonal changes during puberty: V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137877" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hormonal studies and physical maturation in adolescent gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17659215" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Relationship of adolescent gynecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14000906" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Gynecomastia. Its incidence, recognition and host characterization in 447 autopsy cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/429488" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gynecomastia as a physical finding in normal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6997736" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486139" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gynecomastia in a hospitalized male population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1939405" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gynaecomastia and heart failure--adverse drug reaction or disease process?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840497" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7793489" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Unilateral breast masses in men over 40: a diagnostic dilemma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10075303" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Unilateral male breast masses: cancer risk and their evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12007899" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Androgens and mammary growth and neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180949" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Testosterone effects on the breast: implications for testosterone therapy for women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108847" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6354523" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6366826" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The estrogenic and antiestrogenic activities of androgens in female target tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gynecomastia associated with cirrhosis of the liver</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6987837" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The pathogenesis of gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3498912" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gynaecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4271572" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/907238" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pathophysiology of spironolactone-induced gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6301363" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12270030" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Causes of gynaecomastia in young adult males and factors associated with idiopathic gynaecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3818893" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Increased aromatase activity in pubic skin fibroblasts from patients with isolated gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28179453" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gynaecomastia in 786 adult men: clinical and biochemical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1095256" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Gynaecomastia in male adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4757191" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Plasma testosterone and estrogens in pubertal gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/519882" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Twenty-four hour profiles of circulating androgens and oestrogens in male puberty with and without gynaecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24072080" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pubertal gynecomastia coincides with peak height velocity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033660" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Elevated serum IGF-I, but unaltered sex steroid levels, in healthy boys with pubertal gynaecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287961" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A Longitudinal Study of Growth, Sex Steroids, and IGF-1 in Boys With Physiological Gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16355805" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Leptin levels in boys with pubertal gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22862307" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Drug-induced gynecomastia: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28228662" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8094898" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Drug-induced gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25827472" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gynecomastia and drugs: a critical evaluation of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471456" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10419425" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Medical management of aldosterone-producing adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668699" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28090229" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29923212" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Statin medications and the risk of gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341839" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Gynecomastia associated with calcium channel blocker therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8136667" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21641801" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Spectrum of breast disease encountered in HIV-positive patients at a community teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125753" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efavirenz-associated gynecomastia: report of five cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31393563" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lavender Products Associated With Premature Thelarche and Prepubertal Gynecomastia: Case Reports and Endocrine-Disrupting Chemical Activities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3352686" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The mortician's mystery. Gynecomastia and reversible hypogonadotropic hypogonadism in an embalmer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583418" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Epidemic of gynecomastia among haitian refugees: exposure to an environmental antiandrogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558589" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Environmental gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35663791" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prevalence of endocrine disorders among children exposed to Lavender Essential Oil and Tea Tree Essential Oils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15055353" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Soy protein formulas in children: no hormonal effects in long-term feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8279155" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Androgen deficiency and aging in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2310274" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Gynecomastia and cirrhosis of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1133151" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Conversion of androgens to estrogens in cirrhosis of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18911010" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Gynecomastia following severe starvation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/807594" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The pituitary-gonadal axis in men with protein-calorie malnutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/457848" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Kinetics of human chorionic gonadotropin-induced steroidogenic response of the human testis. II. Plasma 17 alpha-hydroxyprogesterone, delta4-androstenedione, estrone, and 17 beta-estradiol: evidence for the action of human chorionic gonadotropin on intermediate enzymes implicated in steroid biosynthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27229339" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : CT measurement of breast glandular tissue and its association with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31063146" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Is gynecomastia related to the disease characteristics and prognosis in testicular germ cell tumor patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6177295" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Gynecomastia after cytotoxic therapy for metastatic testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1090360" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6795227" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Leydig cell tumor with gynecomastia: hormonal effects of an estrogen-producing tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990169" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Leydig cell tumour of the testis: presentation, therapy, long-term follow-up and the role of organ-sparing surgery in a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10731125" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Aromatase and gynecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4405908" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Status of estrogen-androgen balance in hyperthyroid men with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5536390" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Gynecomastia and mastoplasia in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10715765" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Gynaecomastia as a presenting feature of thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5071339" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hyperthyroidism and gynecomastia: metabolic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4134992" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sex-hormone-binding globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524563" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hypothalamic-pituitary-testicular axis and seminal parameters in hyperthyroid males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1166483" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Estrogen metabolism in hyperthyroidism and in cirrhosis of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5658367" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Gynecomastia: an endocrinologic complication of hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/870823" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The pituitary-testicular axis in men with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14264352" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : FEMINIZING ADRENOCORTICAL TUMORS IN THE MALE. A REVIEW OF 52 CASES INCLUDING A CASE REPORT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115870" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Feminizing adrenal neoplasms: case presentations and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115870" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Feminizing adrenal neoplasms: case presentations and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115870" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Feminizing adrenal neoplasms: case presentations and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7671849" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Androgen receptor defects: historical, clinical, and molecular perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412043" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, reproductive hormones and the development of gynaecomastia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15483104" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3924954" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Familial gynecomastia with increased extraglandular aromatization of plasma carbon19-steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12736278" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064691" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Genomic basis of aromatase excess syndrome: recombination- and replication-mediated rearrangements leading to CYP19A1 overexpression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311795" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : An aroma of complexity: how the unique genetics of aromatase (CYP19A1) explain diverse phenotypes from hens and hyenas to human gynecomastia, and testicular and other tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25264451" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24716396" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
